Page 3 - Slide 1
P. 3
Program Faculty
Disclosures
Sebastien J. Hotte, MD, MSC (HRM), FRCPC • Consultant/advisor – Astellas, AstraZeneca, Bayer, Janssen
Medical Oncologist, Juravinski Cancer Centre • Grants/honorarium – BMS, Janssen
Associate Professor, Dept. of Oncology, McMaster University • Clinical trials – Astellas, Bayer, BMS, Merck, Pfizer, Roche
John S. Kell BA, MD, FRCSC • Consultant/advisor – Abbott, Amgen, AstraZeneca, Ferring, Genomic
Division Head Urology, Michael Garron Hospital Health, GSK, J&J, Merus, Pfizer, Takeda, Tersera
Toronto East Health Network • Grants/honorarium – Abbott, Amgen, AstraZeneca, Ferring, Genomic
Section Chair Urology Ontario Medical Association Health, GSK, J&J, Merus, Pfizer, Takeda, Tersera
Tamim Niazi, MDCM • Consultant/advisor – P COC, GURC
Radiation Oncologist, Jewish General Hospital • Grants/honorarium – Abbvie, Allergan, Amgen, Astellas,
Associate Professor, Dept. of Oncology, McGill University AstraZeneca, Bayer, Janssen, Sanofi, Tersera
• Clinical trials – Astellas, AstraZeneca, Bayer, Janssen, Sanofi,
Tersera
Ricardo Rendon, MD, FRCSC • Consultant/advisor – Abbott, Amgen, Astellas, Bayer, Ferring, Janssen
Professor, Department of Urology • Speakers’ bureau – Amgen, Astellas, Ferring, Janssen
Nova Scotia Health Authority & Dalhousie University • Grants/honorarium – Astellas, Amgen, Bayer, Janssen
Chair, Genitourinary Cancer Site Team, • Clinical trials – Abbvie, Amgen, Astellas, Bavarian Nordic, Ferring,
Nova Scotia Health Authority Cancer Program Janssen
VP Education, Canadian Urological Association
3
